Scarica l'app Stockscreener
8.74
1.47%
0.21
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Market Catalysts: How much upside does Xilio Therapeutics Inc have2026 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Xilio plans mid-2026 IND filing for cancer therapy XTX501 By Investing.com - Investing.com Australia
Xilio Therapeutics Extends Cash Runway Through 2027 and Advances Masked Immuno-Oncology Pipeline, Including XTX501 and Multi-Specific T Cell Engagers 123 - Minichart
Xilio Therapeutics: Advancing Masked Immuno-Oncology Therapies for Improved Cancer Outcomes - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xilio plans mid-2026 IND filing for cancer therapy XTX501 - Investing.com
Xilio Therapeutics 2025 10-K: Revenue $43.8M, EPS (loss) $0.00 - TradingView
Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals - Stock Titan
XLO: Collaboration revenue surged and cash runway extended as pipeline advanced toward key milestones - TradingView
Xilio (NASDAQ: XLO) boosts 2025 revenue and cash runway into 2027 - Stock Titan
BRIEF-Xilio Therapeutics Q4 Net Income USD 10.36 Million - TradingView
Cancer drug developer targets 2026 trial start with cash into 2027 - Stock Titan
Xilio Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO) - Stock Titan
Volume Summary: Can Xilio Therapeutics Inc deliver alphaWeekly Stock Summary & Daily Entry Point Alerts - baoquankhu1.vn
Trading Recap: What is the long term forecast for Xilio Therapeutics Inc stockGold Moves & Community Consensus Picks - baoquankhu1.vn
Can Xilio Therapeutics Inc sustain earnings growthWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Exit Recap: Will Boyd Gaming Corporation stock benefit from M A2026 EndofMonth & Weekly Return Optimization Plans - baoquankhu1.vn
Big Picture: Why is Xilio Therapeutics Inc stock going downWeekly Risk Report & Proven Capital Preservation Methods - baoquankhu1.vn
Analysis Recap: Whats the outlook for JB Hunt Transport Services Incs sector2026 Selloffs & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Xilio Therapeutics to present data on masked cancer therapy at AACR - Investing.com Australia
Xilio Therapeutics to present data on masked cancer therapy at AACR By Investing.com - Investing.com South Africa
Xilio Therapeutics to Present Poster on XTX601 at AACR Annual Meeting 2026 - Quiver Quantitative
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program ... - Bluefield Daily Telegraph
Xilio Therapeutics to Present New Preclinical Data for its - GlobeNewswire
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8%What's Next? - MarketBeat
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Sahm
Inflation Data: Whats the fair value of Xilio Therapeutics Inc stock2026 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Trading Halt: Halted at 7:50:00 p.m. ETTrading Halt: Halt News PendingXilio Therapeutics (NASDAQ:XLO) - Benzinga
Xilio Therapeutics implements 1-for-14 reverse stock split By Investing.com - Investing.com Canada
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - The Globe and Mail
Published on: 2026-03-13 07:54:21 - baoquankhu1.vn
Xilio Therapeutics implements 1-for-14 reverse stock split - Investing.com South Africa
Xilio Therapeutics (Nasdaq: XLO) enacts 1-for-14 reverse stock split - Stock Titan
XLO Forecast, Price Target & Analyst Ratings | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Xilio Therapeutics Advances Masked Immuno-Oncology Therapies with Robust Pipeline, Strategic Partnerships, and Strong Financials (2026 Update) - Minichart
Xilio Therapeutics Updates Investor Presentation on I-O Strategy - TipRanks
Xilio Therapeutics posts investor presentation highlighting pipeline, $137.5M cash and upcoming INDs - TradingView
Cash runway to 2027: Xilio Therapeutics (NASDAQ: XLO) details I-O pipeline - Stock Titan
XLO SEC FilingsXilio Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Can Xilio Therapeutics Inc expand into new marketsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Institution Moves: How sustainable is Xilio Therapeutics Inc. stock dividend payout2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Naître et grandir
Chipmakers Recap: Is Xilio Therapeutics Inc benefiting from innovation trendsJuly 2025 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Xilio Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Press Release: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
Xilio Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
XLO PE Ratio & Valuation, Is XLO Overvalued - Intellectia AI
Is Xilio Therapeutics Inc. benefiting from innovation trendsPortfolio Performance Report & Free Technical Confirmation Trade Alerts - mfd.ru
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):